ADR (QNRX) stock price has shown some volatility, fluctuating -40.30% over the last five trades and -34.67% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Quoin Pharmaceuticals (QNRX – Research Report) and keeping the price target at ...
ADR (QNRX) stock price has shown some volatility, fluctuating -35.40% over the last five trades and -33.06% over the past 30 trades. This represents a notable shift from earlier in the year. Over the ...
The information for this report is sourced from a press release statement filed by Quoin Pharmaceuticals with the SEC. The stock currently trades at $0.41, near its 52-week low of $0.42, reflecting ...
After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ...
Quoin Pharmaceuticals has announced new clinical data indicating the need for ongoing treatment with QRX003 for patients with Netherton Syndrome, as all positive effects observed during a 12-week ...
(RTTNews) - Quoin Pharmaceuticals, Inc. (QNRX), a clinical-stage specialty pharmaceutical company, on Thursday, announced additional clinical data supporting the efficacy of its investigational ...
ASHBURN, Va., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan ...
Jan. 23, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback